sellWeak cluster of 310b5-1 plan
Carl Dambkowski sold $1.5M of APGE
Chief Medical Officer at Apogee Therapeutics, Inc.. 18,700 shares at an average of $77.84, traded Jan 7, 2026, filed Jan 9, 2026.
Warning score
20Value
$1.5M
18,700 shares
Holdings after
212,523
-8% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$1.5M at market
- 0Share of holdings soldSold 8.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-26-002574, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 7, 2026 | MOption exercise Common Stock10b5-1 | +14,025 | $22.86 | $321k | 231,223 | Jan 9, 2026 |
| Jan 7, 2026 | SOpen-market sale Common Stock10b5-1 | -2,954 | $77.13 | $228k | 228,269 | Jan 9, 2026 |
| Jan 7, 2026 | SOpen-market sale Common Stock10b5-1 | -14,820 | $77.90 | $1.2M | 213,449 | Jan 9, 2026 |
| Jan 7, 2026 | SOpen-market sale Common Stock10b5-1 | -826 | $79.04 | $65k | 212,623 | Jan 9, 2026 |
| Jan 7, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $80.06 | $8,006 | 212,523 | Jan 9, 2026 |
| Jan 7, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,025 | $0.00 | $0 | 139,540 | Jan 9, 2026 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $170k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.5M 20,000 shares | -2% | |
| 11Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $391k 5,500 shares | -3% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $140k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.3M 20,000 shares | -2% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $132k 2,000 shares | -1% | |
| 10Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $362k 5,500 shares | -3% | |
| 75Notable | Apogee Therapeutics, Inc. | Fairmount Funds Management LLC director | $134M 1,750,000 shares | -85% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.6M 20,000 shares | -2% | |
| 37Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $609k 8,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.